钴-60剂量率与生物有效剂量对立体定向放射外科治疗颅内脑膜瘤局部控制的重要性
单机构336例患者414个脑膜瘤病灶接受钴源立体定向放射外科治疗,评估剂量率与生物有效剂量对局部控制的影响。剂量率<2.95 Gy/min组5年局部失败率15.6%,≥2.95 Gy/min组4.3%(P=.0375);剂量率每增加1 Gy/min,局部失败调整风险比为0.53。
要点
- 剂量率<2.95 Gy/min组5年局部失败率15.6%,≥2.95 Gy/min组为4.3%(P=.0375)
- 剂量率每增加1 Gy/min,局部失败调整HR为0.53(95%CI 0.29-0.97,P=.041)
- 354个I级或未切除病灶中,BED>50 Gy2.47与局部失败发生率降低相关(P=.0030)
核心结论
- 接受较低剂量率治疗的脑膜瘤患者局部失败发生率高于接受较高剂量率治疗者。
研究设计与样本
- 单机构队列研究,纳入2005年至2018年间接受钴源立体定向放射外科治疗的336例患者共414个独立脑膜瘤病灶。
- BED采用SRS特异性单指数模型计算,考虑每个病灶的治疗时间,假设α/β=2.47 Gy。
- 局部失败累积发生率在考虑死亡竞争风险后按病灶计算,并采用比例风险模型进行多变量分析。
主要发现
- 最常用的SRS剂量为12 Gy(n=227个病灶),140个病灶接受14 Gy。
- 剂量率<2.95 Gy/min组5年局部失败率为15.6%(95%CI 10.4-21.9),≥2.95 Gy/min组为4.3%(95%CI 1.4-9.8),P=.0375。
- 在354个I级或未切除并接受SRS治疗的病灶中,BED>50 Gy2.47与局部失败发生率降低相关(P=.0030)。
- 剂量率每增加1 Gy/min,局部失败的调整风险比为0.53(95%CI 0.29-0.97,P=.041)。
- 处方剂量>12 Gy与局部失败发生率降低无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiosurgery dose rate and biologically effective dose (BED) are associated with outcomes after stereotactic radiosurgery (SRS) for functional neurosurgical conditions and some benign tumors. It is not known if these factors affect the efficacy of SRS for meningioma. OBJECTIVE: To determine the association between cobalt-60 dose rate and BED on outcomes in patients with meningioma treated with SRS. METHODS: A single-institution cohort of 336 patients treated between 2005 and 2018 with cobalt-based SRS for 414 separate meningioma lesions was assembled. BED was calculated using an SRS-specific monoexponential model accounting for treatment time per lesion, assuming α/β = 2.47 Gy. Cumulative incidences of local failure (LF) were reported after considering the competing risk of death, on a per-lesion basis. Multivariable analysis of LF was performed using a proportional hazards model. RESULTS: The most common SRS dose was 12 Gy (n = 227); 140 lesions received 14 Gy. Five-year LF was 15.6% (95% confidence interval 10.4-21.9) and 4.3% (1.4-9.8) in patients who had a dose rate of <2.95 and ≥2.95 Gy/min, respectively (P = .0375). Among 354 grade I or unresected lesions treated with SRS, BED >50 Gy2.47 was associated with a lower incidence of LF (P = .0030). Each 1 Gy/min increase in dose rate was associated with an adjusted hazard ratio of 0.53 (95% confidence interval, 0.29-0.97, P = .041) for LF. Prescription dose >12 Gy was not associated with a lower incidence of LF. CONCLUSION: Patients with meningiomas treated with lower dose rates experienced a higher incidence of LF than those treated with higher dose rates.
引用
- Huo M, Rose M, van Prooijen M, et al. Importance of Cobalt-60 Dose Rate and Biologically Effective Dose on Local Control for Intracranial Meningiomas Treated With Stereotactic Radiosurgery. Neurosurgery. 2022. PMID: 34982881. doi:10.1227/NEU.0000000000001755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。